Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Tedizolid phosphate (TR-701), formerly torezolid phosphate, an IV and orally administered second generation oxazolidinone, has successfully completed the first of two Phase 3 trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
In addition to Tedizolid phosphate (TR-701), Trius has two ongoing preclinical programs using our proprietary discovery platform to identify and develop antibiotics to treat infections caused by gram-negative and gram–positive bacteria.
Through funding under a contract with the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, our preclinical program targeting GyrB/ParE is focused on identifying and developing novel antibiotics to treat serious infections caused by gram-negative bacterial pathogens.
Our second preclinical program, the MurB program, is funded by a three year contract from the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. In this program, we are working with Lawrence Livermore National Laboratories to discover novel antibacterial agents that target MurB, an essential bacterial cell wall enzyme.